Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

about

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

Item

http://www.wikidata.org/entity/Q47136379

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@en

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@nl

type

Item

label

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@en

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@nl

prefLabel

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@en

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@nl

P1476

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia.

@en

P2093

Cuizhen Zhu

http://www.w3.org/2001/XMLSchema#string

Donghong Cui

http://www.w3.org/2001/XMLSchema#string

Jinghong Chen

http://www.w3.org/2001/XMLSchema#string

Yanmin Peng

http://www.w3.org/2001/XMLSchema#string

Yezhe Lin

http://www.w3.org/2001/XMLSchema#string

Yousong Su

http://www.w3.org/2001/XMLSchema#string

Yuan Shi

http://www.w3.org/2001/XMLSchema#string

Zhiguang Lin

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of the prevalence of schizophrenia.

The TRAF6-NF kappa B signaling pathway in autoimmunity: not just inflammation.

Inflammation and schizophrenia

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders.

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

NF-IL6 and NF-kappa B in cytokine gene regulation.

The beta-chemokines CCL2 and CCL7 are two novel differentiation factors for midbrain dopaminergic precursors and neurons.

Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release.

A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

P304

287-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.11919/J.ISSN.1002-0829.217093

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29276352

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

5738517

http://www.w3.org/2001/XMLSchema#string